Shots:

• The company reported the results from the dose-finding & tolerability clinical study that evaluates ketamine for the treatment of LID in patients with PD
• In an efficacy result, 100% of patients treated with ketamine showed a reduction in dyskinesias as measured by the UDysRS over pre-treatment baseline, was well tolerated with no serious AEs. The results are expected to be submitted for presentation at a medical congress by June 2022
• The company plans to advance the P-III study, based on these results & plans to engage with the US FDA for the ketamine’s approval in a planned P-III clinical study to treat PD under the 505(b)(2) regulatory pathway

Ref: Globe Newswire | Image: Globe Newswire